Citations

Clear

108 citation(s) found for "Sheth, S".

Minimal clinical impact of embolization to new territory on outcomes in medium vessel occlusion strokes treated with mechanical thrombectomy: a retrospective multicenter study
Salim, Hamza , Yedavalli, Vivek , Lakhani, Dhairya A. , Milhem, Fathi , Musmar, Basel , Adeeb, Nimer , Faizy, Tobias D. , Daraghma, Motaz , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Puri, Ajit S., Dyzmann, Christian , Filipe, João Pedro , Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric, Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Salim, Hamza , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Colasurdo, Marco , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Essibayi, Muhammed Amir , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Marnat, Gaultier , Shaikh, Hamza A , Griessenauer, Christoph J , Liebeskind, David S. , Alexandre, Andrea M , Kalsoum, Erwah , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Lakhani, Dhairya , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Clarençon, Frédéric , Siegler, James E. , Nguyen, Thanh N. , Essibayi, Muhammed Amir , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Wintermark, Max , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 5, 2025 | Volume: 18 | Issue: 1 | Pages: 186-194

10.1136/jnis-2024-022570 | PMID 40044412 Get It

Background Mechanical thrombectomy (MT) is established as an effective treatment for large vessel occlusion strokes, but its efficacy and safety for medium vessel occlusions (MeVOs) remain less clear. This study examines the impact of periprocedural embolization to a new vascular territory (ENT) on clinical outcomes in patients with MeVO stroke treated with MT. Methods A multicenter, retrospective analysis was conducted using the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry, including 2122 patients with MeVO stroke w­ho underwent MT between September 2017 and July 2023. ENT was defined as filling defects in previously unaffected territories, excluding embolization near the original occlusion, observed on final angiographic runs after retrieval of the primary thrombus. The associations between ENT, procedural variables, and 90-day clinical outcomes were evaluated, including functional independence (modified Rankin Scale (mRS) scores of 0–2), excellent outcomes (mRS 0–1), mortality, and hemorrhagic complications. Results ENT occurred in 2.9% (63/2122) of patients. Longer onset-to-arterial puncture time (adjusted OR 1.03; 95% CI 1.01 to 1.05; P=0.002) and a greater number of passes (adjusted OR 1.15; 95% CI 1.01 to 1.32; P=0.032) were associated with increased ENT risk, while excellent recanalization (thrombolysis in cerebral infarction (TICI) scale score 2c–3) was associated with reduced ENT risk (adjusted OR 0.41; 95% CI 0.23 to 0.72; P=0.002). ENT was not associated with poorer functional independence, mortality, or hemorrhagic complications. Conclusions ENT during MT for MeVO stroke occurs infrequently and does not significantly affect the clinical outcomes. These findings suggest ENT risk should not deter clinicians from performing MT in patients with MeVO. Further prospective studies are needed to validate these results.
Trends in Readmissions Rates and Mortality after Cardiac Resynchronization Therapy in Patients with Nonischemic Cardiomyopathy
Sheth, Aakash , Patel, Harsh P., Pandya, Krutharth, Prajapati, Kesar , Niar, Ambica, Labedi, Mohamed, Deshmukh, Abhishek , Deshmukh, Abhishek, Prajapati, Kesar , Patel, Harsh P., Pandya, Krutharth, Thakkar, Samarthkumar , Niar, Ambica, DeSimone, Christopher V. , Deshmukh, Abhishek

Mayo Clinic

Current Cardiology Reviews | March 4, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.2174/011573403x345244250217052010 | PMID 40033589 Get It

Introduction: Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real- world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit. Methods: We searched the National Readmissions Database (NRD) from 2016-2020 to identify hospitalizations with NICM using appropriate ICD-10 diagnosis and procedure codes. The cohort was further divided into groups with NICM and CRT-D implantation and NICM with CRTP implantation. Results and Discussion: Our final cohort included 8,801 hospitalizations with NICM and CRT-D implantation and 3,399 hospitalizations with NICM and CRT-P implantation. Propensity matching was performed using comorbidities through multivariate logistic regression. Two thousand nine hundred seventeen hospitalizations were included in each of the two groups, CRT-D and CRT-P. Analysis of the propensity-matched cohorts at 180 days revealed a trend toward lower heart failure readmission, all-cause readmission, and all-cause mortality rates in the group with CRTP implantation. However, there was no difference noted in the 180-day hazard ratios of HF readmission [1.08 (0.98-1.19); p = 0.1], all-cause readmission [1.04 (0.87-1.12); p = 0.23], and all-cause mortality [0.83 (0.58-1.19); p = 0.32]. Conclusion: It was found that NICM patients with CRT-D have a trend towards higher HF readmissions, all-cause readmission, and all-cause mortality compared to those with CRT-P, but no significant difference was noted in hazard ratios. The findings of our study raise further questions about the need for defibrillator therapy in patients with NICM and merit further studies to better select candidates for each of these therapies.
Epilepsy Surgery Education: A Survey of US Epilepsy Fellowship Program Directors
Katyal, Roohi , Gutierrez, Camilo , Day, Brian K., Gavvala, Jay R. , Sheth, Sameer A. , Gavvala, Jay R , Sheikh, Irfan , Sinha, Saurabh R. , Wirrell, Elaine , Beniczky, Sándor , Nascimento, Fábio A.

Mayo Clinic

Journal of Clinical Neurophysiology | February 12, 2025 | Volume: 43 | Issue: 1 | Pages: 1-8

10.1097/wnp.0000000000001144 | PMID 39934975 Get It

Purpose: To understand the current state of epilepsy surgery education delivered to epilepsy fellows in the United States. Methods: An online survey focused on characteristics of epilepsy surgery education was distributed to all 93 epilepsy fellowship program directors listed on the ACGME website (accessed in May 2022). Programs were stratified per the number of fellows currently enrolled: 0 to 3 (group A) and ≥4 (group B). Results: Forty-one of 93 (44%) epilepsy fellowship programs were included in the study. The average number of resective surgeries, ablations, or corpus callosotomies per year was mostly 0 to 30 (54%) in group A and mostly >30 (80%) in group B ( P = 0.05). The average number of intracranial implantations per year was mostly 0 to 20 (58%) in group A and mostly >20 (80%) in group B ( P < 0.05). The average number of neurostimulation implantations per year was 15 (range 0–90; vagal nerve stimulation), 7 (range 0–25; responsive neurostimulation), and 4 (range 0–10; deep brain stimulation). In 78% of programs, fellows are not required to present a minimum number of epilepsy surgery cases in multidisciplinary conference before graduation. Roughly half of programs (51%) reported not using objective measures to assess fellow competency in epilepsy surgery. Conclusions: Our results suggest significant variability in epilepsy surgery volume and, consequently, fellow exposure to surgical cases and lack of standardized, objective measures in fellow teaching and assessment in the field of epilepsy surgery across programs in the United States. We advocate development of a core epilepsy surgery curriculum including minimum standards at the national level.
Impact of smoking on recurrence rates among wide-neck intracranial aneurysms treated with Woven EndoBridge: a multicenter retrospective study
Vaishnav, Dhrumil , Adeeb, Nimer , Aslan, Assala , Cancelliere, Nicole M., McLellan, Rachel , Ghozy, Sherief, Lay, Sovann V. , Guenego, Adrien , Premat, Kévin , Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza, Župančić, Vedran , Ayberk, Gıyas , Güneş, Yasin Celal , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M., Hassan, A. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Martinez-Gutierrez, Juan Carlos, Sheth, Sunil G. , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S., Pero, Guglielmo , Nossek, Erez , Raz, Eytan, Griessenauer, Christoph J., Asadi, Hamed , Siddiqui, Adnan, Brook, Allan , Haranhalli, Neil , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter, Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula I., Clarençon, Frédéric, Cuellar-Saenz, Hugo H., Patel, Aman B. , Altschul, David , _, _, Spears, Julian , Sundararajan, Sri Hari , Balush, Ali Al, Inoue, Yasuaki , Mirshahi, Shervin , Harker, Pablo, Tutino, Vincent M., Brehm, Alex , Diestro, Jose Danilo B , Shotar, Eimad , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Essibayi, Muhammed Amir , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A., Tawk, Rabih G. , Panni, Pietro , Puri, Ajit S , Raz, Eytan , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Aziz‐Sultan, Mohammad Ali , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Limbucci, Nicola , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Dibas, Mahmoud , Vranic, Justin E. , Alotaibi, Naif M. , Harker, Pablo , Sporns, Peter Bernhard

Mayo Clinic

Journal of Neurosurgery | January 31, 2025 | Volume: 142 | Issue: 6 | Pages: 1732-1740

10.3171/2024.10.jns241058 | PMID 39889291 Get It

OBJECTIVE Tobacco smoking is among the factors known to significantly augment the risk of untreated intracranial aneurysm (IA) growth and rupture. Smoking appears to have a variable effect on different endovascular treatment modalities. The impact of smoking on the safety, efficacy, and outcomes of Woven EndoBridge (WEB) device use for wide-neck IAs has not been evaluated. This study aimed to investigate the outcomes of WEB devices by smoking status. METHODS A retrospective multicenter analysis was conducted on the data of patients from 36 sites worldwide treated with the WEB device for intracranial saccular aneurysms. Patients were stratified based on smoking status (current, former, and never smokers). The Student t-test and chi-square test were performed for continuous and categorical variables, respectively. Multivariable logistic regression was used to adjust for confounders. RESULTS Of 1376 patients with available smoking status, 504 were current smokers, 358 were former smokers, and 514 were never smokers. Upon adjusting for significant confounders, no association was found between smoking and recurrence outcomes (OR 1.39, 95% CI 0.69–2.80; p = 0.36), thromboembolic and hemorrhagic complications, and mortality among IAs treated with the WEB device. There was no statistically significant difference in outcomes between former and never smokers (OR 1.23, 95% CI 0.70–2.18; p = 0.46). The location of aneurysms differed between smoking groups, with former smokers having more anterior circulation aneurysms compared with current and never smokers (99.0% vs 96.9% vs 95.3%; p = 0.01). In terms of clinical symptoms, headache and dizziness were more common in the never smokers compared with current and former smokers (13.9% vs 8.9% vs 7.7%, p = 0.01). CONCLUSIONS This large-scale study suggests no significant correlation between smoking and the recurrence of IAs treated with the WEB device. Biological studies are warranted to better understand the biological impact of smoking on the growth and rupture of treated IAs.
Abstract 108: APOE Epsilon 4 Carriers Derive Greater Benefit from Genetically Reduced Factor XI Levels
Huo, Shufan, Ohno‐Machado, Lucila , Falcone, Guido J. , Clocchiatti‐Tuozzo, Santiago , Rivier, Cyprien , Huo, Shufan , Hawkes, Maximiliano A. , Schwamm, Lee H. , Sheth, Kevin N. , Gill, Thomas M.

Mayo Clinic

Stroke | January 30, 2025 | Volume: 56 | Issue: Suppl_1 | Pages: No page available

10.1161/str.56.suppl_1.108 Get It

Introduction: Coagulation factor XI (FXI) inhibitors have shown a better safety profile than other anticoagulants, offering similar reductions in ischemic stroke (IS) risk with a lower risk of intracerebral hemorrhage (ICH). The APOE ε4 genotype is associated with increased risks of both IS and ICH, likely due to its effects on lipid levels, intracranial atherosclerosis, and cerebral amyloid angiopathy. We hypothesized that APOE ε4 carriers would gain greater therapeutic benefit from genetically reduced FXI levels compared to non-carriers. Methods: We conducted a two-stage Mendelian randomization (MR) analysis using the random-effects, inverse-variance weighted method. First, we estimated the effect of genetically proxied FXI inhibition on IS and ICH risk in the general population using summary data from genome-wide association studies of FXI levels (16,169 participants), IS (1,503,898 controls and 110,182 cases), and ICH (3,745 controls and 3,226 cases). Second, we performed stratified analyses to estimate the effect of genetically determined FXI levels on IS (10,343 cases and 476,838 controls) and ICH (2,236 cases and 484,945 controls) risk across APOE ε4 carriership strata (0, 1, or 2 alleles) using UK Biobank data. Results: In the general population, random-effects, inverse-variance weighted MR analyses showed that every 1 unit decrease in natural log-transformed FXI levels was associated with a 37% reduction in IS risk (OR:0.63; 95%CI:0.52–0.77; p <0.001) without a significant increase in ICH risk (OR:0.86; 95%CI:0.37–2.00; p =0.73). Stratified MR analyses indicated that genetically determined reductions in FXI levels had varying protective effects on IS risk based on APOE ε4 status: 31% in non-carriers (OR:0.69, 95%CI:0.53–0.91; p =0.008), 43% in carriers of 1 allele (OR:0.57, 95%CI:0.36–0.91; p =0.02), and 75% in carriers of 2 alleles (OR:0.25, 95%CI:0.06–1.06; p =0.06). Similar MR analyses showed no significant increase in ICH risk with genetically determined reductions in FXI levels in any APOE ε4 strata (all p >0.38, Figure 1). Conclusion: This two-stage genetic study provides causal evidence that lower FXI levels reduce IS risk in the general population, with an even stronger effect among APOE ε4 carriers, while not increasing ICH risk. These results indicate that FXI inhibitors might be a safer and more effective alternative to other anticoagulants among APOE ε4 carriers, who are known to be at higher risk for both ischemic and hemorrhagic events.
Efficacy and safety of mechanical thrombectomy in distal medium middle cerebral artery occlusion ischemic stroke patients on low-dose aspirin
Salim, Hamza , Yedavalli, Vivek , Milhem, Fathi , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Rouchaud, Aymeric, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marrota, Thomas, Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Griessenaur, Christoph, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Salim, Hamza , Henninger, Nils , Tan, Benjamin Yq , Cancelliere, Nicole M , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Clarençon, Frédéric , Siegler, James E , Nguyen, Thanh N , Essibayi, Muhammed Amir , Gonzalez, Nestor R , Pedicelli, Alessandro , Alexandre, Andrea M , Faizy, Tobias D , Guenego, Adrien , Dmytriw, Adam A , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Regenhardt, Robert W , Yedavalli, Vivek S , Varela, Ricardo , Musmar, Basel , Daraghma, Motaz , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Marotta, Thomas R. , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Essibayi, Muhammed Amir , Costalat, Vincent , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Tancredi, Illario , Wintermark, Max , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

International Journal of Stroke | January 29, 2025 | Volume: 20 | Issue: 6 | Pages: 669-678

10.1177/17474930251317883 | PMID 39873268 Get It

Background: Acute ischemic stroke (AIS) from distal medium vessel occlusion (DMVO) presents unique treatment challenges. Mechanical thrombectomy (MT) is emerging as a viable option for these patients, yet the role of pre-stroke aspirin treatment is unclear. This study evaluates the impact of pre-stroke low-dose aspirin on outcomes in DMVO patients undergoing MT. Methods: We conducted a multinational, multicenter, propensity score-weighted analysis within the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry. Patients with AIS due to DMVO, treated with MT, were included. We compared outcomes between patients on pre-stroke low-dose aspirin (75–100 mg) and those not on antiplatelet therapy. The primary outcome was functional independence at 90 days (modified Rankin Scale (mRS), 0–2). Secondary outcomes included excellent functional outcome at 90 days (mRS, 0–1), mortality, and day 1 post-MT National Institutes of Health Stroke Scale (NIHSS) score. Safety outcomes focused on hemorrhagic complications, including symptomatic intracerebral hemorrhage (sICH). Results: Among 1354 patients, 150 were on pre-stroke low-dose aspirin. After applying inverse probability of treatment weighting (IPTW), aspirin use was associated with significantly better functional outcomes (mRS, 0–2: odds ratio (OR) = 1.89, 95% confidence interval (CI) = 1.14 to 3.12) and lower 90-day mortality (OR = 0.56, 95% CI = 0.32 to 1.00). The aspirin group had lower NIHSS scores on day 1 (β = −1.5, 95% CI = −2.8 to −0.27). The sICH rate was not significantly different between the groups (OR = 0.92, 95% CI = 0.60 to 1.43). Conclusions: Pre-stroke low-dose aspirin was associated with improved functional outcomes and reduced mortality in patients with DMVO undergoing MT, without a significant increase in sICH. These findings suggest that low-dose aspirin may be safe and associated with more frequent excellent outcomes for this patient population. Further prospective studies are needed to validate these results and assess long-term outcomes.
Clinical outcomes of patients with unsuccessful mechanical thrombectomy versus best medical management of medium vessel occlusion stroke in the middle cerebral artery territory
Faizy, Tobias D. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya A. , Musmar, Basel , Adeeb, Nimer , Essibayi, Muhammed Amir , Daraghma, Motaz , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Puri, Ajit S., Dyzmann, Christian , Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus A, Costalat, Vincent , Gory, Benjamin, Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Valente, Iacopo , Salim, Hamza , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Colasurdo, Marco , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Marnat, Gaultier , Shaikh, Hamza A , Griessenauer, Christoph J , Liebeskind, David S. , Alexandre, Andrea M , Kalsoum, Erwah , Mendes Pereira, Vitor , Dmytriw, Adam A , Guenego, Adrien , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Lakhani, Dhairya , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Siegler, James E. , Nguyen, Thanh N. , Möhlenbruch, Markus , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Wintermark, Max , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | January 23, 2025 | Volume: 18 | Issue: 1 | Pages: 155-165

10.1136/jnis-2024-022642 | PMID 39855674 Get It

Background Current randomized controlled trials are investigating the efficacy and safety of mechanical thrombectomy (MT) in patients with medium vessel occlusion (MeVO) stroke. Whether best medical management (MM) is more efficient than unsuccessful vessel recanalization during MT remains unknown. Methods This was a retrospective cohort study using data from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. Only patients with occlusion of the distal branches (M2 and M3) of the middle cerebral artery territory were included. Unsuccessful MT was defined as a modified Thrombolysis in Cerebral Infarction score of 0–2a. Propensity score matching was used to control for confounders. The primary outcome was functional independence, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after treatment. Multivariable regression analysis was used to assess factors associated with the primary outcome. Results Of 2903 patients screened for eligibility, 532 patients were analyzed (266 per group) after propensity score matching. The MM group had superior functional outcomes, with 32% achieving mRS 0–1 at 90 days compared with 21% in the MT group (P=0.011). Patients in the MM group also had significantly lower rates of symptomatic intracranial hemorrhage (sICH) (3.4% vs 16%, P<0.001) and any hemorrhage (18% vs 48%, P<0.001). On multivariable regression, unsuccessful MT was associated with reduced odds of functional independence (OR 0.50, 95% CI 0.29 to 0.85, P=0.011) and increased odds of sICH (OR 4.32, 95% CI 1.84 to 10.10, P<0.001). Mortality rates were similar between groups (27% in MM vs 29% in MT, P=0.73). Conclusion Unsuccessful MT for MeVO was linked to worse outcomes than best MM. These findings highlight the risks of prolonged attempts and emphasize the importance of efficient procedural decision-making to reduce complications and improve patient outcomes.
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Davar, Diwakar , Carneiro, Benedito A. , Dy, Grace K. , Harrington, Kevin J. , Patel, Sandip Pravin , Samson, Adel , Agrawal, Sonia, Fan, Chunling , Gong, Maozhen , Burton, J.L., Tu, Eric , Durham, Nicholas M. , Laubscher, Kevin, Arnaldez, Fernanda I. , Zamarin, Dmitriy , Harrington, Kevin , Davar, Diwakar , Sheth, Siddharth H , Borad, Mitesh J. , Galanis, Evanthia , Agrawal, Sonia, Chen, Yuyan , Burton, Jenny

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 17, 2024 | Volume: 12 | Issue: 11 | Pages: e009336

10.1136/jitc-2024-009336 | PMID 39551600 Get It

Background MEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant programmed cell death-1/programmed cell death ligand-1 (PD-L1) axis blockade. Durvalumab is an anti-PD-L1 immune checkpoint inhibitor approved for the treatment of various solid tumors. We describe the results of the first-in-human study combining intravenous MEDI5395 with durvalumab in patients with advanced solid tumors. Methods This phase I, open-label, multicenter, dose-escalation, dose-expansion study recruited adult patients with advanced solid tumors, who had relapsed or were refractory or intolerant to ≥1 prior line of standard treatment. MEDI5395 was administered intravenously as six doses over 15–18 days. The dose-escalation phase assessed four-dose levels (108, 109, 1010, 1011 focus forming units (FFU)) of MEDI5395, with sequential or delayed durvalumab. Durvalumab 1500 mg was administered intravenously every 4 weeks up to 2 years. The dose-expansion phase was not initiated. The primary objectives were to evaluate safety and tolerability, dose-limiting toxicities (DLTs) and the dose and schedule of MEDI5395 plus durvalumab administration. Secondary objectives included the assessment of the efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MEDI5395. Results 39 patients were treated with MEDI5395; 36 patients also received durvalumab. All 39 patients experienced ≥1 treatment-emergent adverse event (TEAE), most commonly fatigue (61.5%), nausea (53.8%) and chills (51.3%). Grade 3–4 TEAEs occurred in 27 (69.2%) patients; these were deemed MEDI5395-related in 12 (30.8%) patients. Two patients experienced a DLT, and the maximum tolerated dose of MEDI5395 with sequential and delayed durvalumab at study termination was 1011 and 1010 FFU, respectively. Four patients (10.3%) achieved a partial response (PR). Patients with PR or stable disease tended to have higher baseline PD-L1 and CD8+ levels in their tumor tissue. A tendency to dose-dependent pharmacokinetics of the viral genome was observed in whole blood and a tendency to dose-dependent viral shedding was observed in saliva and urine. Neutralizing antibodies were observed in all patients but did not appear to impact efficacy negatively. Conclusion This study demonstrates the feasibility, safety and preliminary efficacy of MEDI5395 with durvalumab in patients with advanced solid tumors. Trial registration number NCT03889275
Predictors and Outcomes of Excellent Recanalization Versus Successful Recanalization After Thrombectomy in Proximal and Distal Medium Vessel Occlusion Strokes: A Multinational Study
Yedavalli, Vivek , Salim, Hamza , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Ghozy, Sherief, Heit, Jeremy J. , Regenhardt, Robert W. , Puri, Ajit S., Dyzmann, Christian , Barreau, Xavier , Renieri, Leonardo, Filipe, João Pedro , Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S., Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Investigators, the MAD MT, Liebeskind, David S. , Salim, Hamza , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Gonzalez, Nestor R , Regenhardt, Robert W , Yedavalli, Vivek S , Henninger, Nils , Alexandre, Andrea M , Varela, Ricardo , Musmar, Basel , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Scarcia, Luca , Tan, Benjamin Yong‐Qiang , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Essibayi, Muhammed Amir , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Ota, Takahiro , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Pedicelli, Alessandro , Mendes Pereira, Vitor , Dmytriw, Adam A. , Investigators, the MAD MT

Mayo Clinic

Stroke: Vascular and Interventional Neurology | October 26, 2024 | Volume: 4 | Issue: 6 | Pages: No page available

10.1161/svin.124.001421 | PMID 41583405 Get It

Background Acute ischemic stroke arising from medium vessel occlusions (MeVO) poses substantial challenges in treatment and management. This study aims to elucidate the outcomes and factors contributing to achieving excellent recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] 2c–3) versus successful recanalization (mTICI 2b) in patients with MeVO stroke undergoing mechanical thrombectomy (MT). Methods We conducted a multinational study analyzing data from the MAD‐MT (Multicenter Analysis of Distal Medium Vessel Occlusions: Effect of Mechanical Thrombectomy) registry, encompassing 37 centers across North America, Asia, and Europe, collected between September 2017 and July 2023. The study included acute ischemic stroke patients with MeVO treated with MT, with or without intravenous thrombolysis, who achieved mTICI 2b–3 post‐MT. Results Among 1463 patients with successful recanalization (mTICI 2b–3), 523 achieved mTICI 2b recanalization, and 940 achieved mTICI 2c–3. Distal occlusions exhibited higher odds of excellent recanalization compared with proximal MeVO vessel occlusions (odds ratio, 1.58; 95% CI, 1.17–2.15; P = 0.003). Cardioembolic stroke pathogenesis was associated with a higher likelihood of excellent recanalization (1.67; 95% CI, 1.07–2.59; P = 0.018). Patients achieving mTICI 2c–3 recanalization demonstrated lower initial National Institutes of Health Stroke Scale scores, significant improvements in postprocedural National Institutes of Health Stroke Scale shift, and a higher percentage of favorable 90‐day outcomes compared with those with mTICI 2b. However, no significant difference in 90‐day mortality rates was observed. Conclusion This study underscores that among patients with MeVO stroke with successful recanalization (mTICI 2b–3) there is higher likelihood of achieving excellent recanalization (mTICI 2c–3) in distal occlusions and cardioembolic pathogenesis. mTICI 2c–3 scores post‐MT correlate with improved clinical outcomes compared with mTICI 2b, affirming the superiority of excellent recanalization over successful recanalization in patients with MeVO stroke. Further prospective studies and randomized controlled trials are warranted for validation.